In the latest session, Zimmer Biomet Holdings Inc (NYSE: ZBH) closed at $124.01 down -0.28% from its previous closing price of $124.36. In other words, the price has decreased by -$0.35 from its previous closing price. On the day, 740129 shares were traded. ZBH stock price reached its highest trading level at $124.92 during the session, while it also had its lowest trading level at $123.64.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a deeper understanding of Zimmer Biomet Holdings Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 61.16 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 25.98. For the most recent quarter (mrq), Quick Ratio is recorded 0.78 and its Current Ratio is at 1.61. In the meantime, Its Debt-to-Equity ratio is 0.48 whereas as Long-Term Debt/Eq ratio is at 0.40.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Evercore ISI on January 04, 2024, Downgraded its rating to In-line and sets its target price to $125 from $135 previously.
On October 20, 2023, ROTH MKM started tracking the stock assigning a Neutral rating and target price of $120.
BTIG Research Upgraded its Neutral to Buy on August 28, 2023, while the target price for the stock was maintained at $139.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 22 when Phipps Chad F sold 26,156 shares for $128.62 per share. The transaction valued at 3,364,126 led to the insider holds 44,145 shares of the business.
Jafry Syed A. bought 2,135 shares of ZBH for $223,641 on Nov 09. The Director now owns 4,060 shares after completing the transaction at $104.75 per share. On Aug 30, another insider, Kolli Sreelakshmi, who serves as the Director of the company, bought 1,000 shares for $120.37 each. As a result, the insider paid 120,370 and bolstered with 1,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZBH now has a Market Capitalization of 25.43B and an Enterprise Value of 30.93B. As of this moment, Zimmer’s Price-to-Earnings (P/E) ratio for their current fiscal year is 25.37, and their Forward P/E ratio for the next fiscal year is 14.26. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.66. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.44 while its Price-to-Book (P/B) ratio in mrq is 2.04. Its current Enterprise Value per Revenue stands at 4.18 whereas that against EBITDA is 13.93.
Stock Price History:
Over the past 52 weeks, ZBH has reached a high of $149.25, while it has fallen to a 52-week low of $102.00. The 50-Day Moving Average of the stock is 123.36, while the 200-Day Moving Average is calculated to be 122.98.
Shares Statistics:
For the past three months, ZBH has traded an average of 1.75M shares per day and 1.46M over the past ten days. A total of 205.60M shares are outstanding, with a floating share count of 204.84M. Insiders hold about 0.11% of the company’s shares, while institutions hold 90.82% stake in the company. Shares short for ZBH as of Feb 15, 2024 were 4.17M with a Short Ratio of 2.38, compared to 4.11M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.04% and a Short% of Float of 2.62%.
Dividends & Splits
According to the company, the forward annual dividend rate for ZBH is 0.96, from 0.96 in the trailing year. Against a Trailing Annual Dividend Yield of 0.77%, it implies a Forward Annual Dividend Yield of 0.77%. The stock’s 5-year Average Dividend Yield is 0.74.
Earnings Estimates
There are 23 different market analysts currently analyzing its stock. On average, analysts expect EPS of $1.88 for the current quarter, with a high estimate of $1.96 and a low estimate of $1.8, while EPS last year was $1.89. The consensus estimate for the next quarter is $2.02, with high estimates of $2.1 and low estimates of $1.96.
Analysts are recommending an EPS of between $8.11 and $7.85 for the fiscal current year, implying an average EPS of $8.05. EPS for the following year is $8.68, with 24 analysts recommending between $8.91 and $8.39.
Revenue Estimates
A total of 21 analysts believe the company’s revenue will be $1.87B this quarter.It ranges from a high estimate of $1.91B to a low estimate of $1.85B. As of the current estimate, Zimmer Biomet Holdings Inc’s year-ago sales were $1.7B, an estimated increase of 9.80% from the year-ago figure. For the next quarter, 21 analysts are estimating revenue of $1.96B, an increase of 7.50% less than the figure of $9.80% in the same quarter last year. There is a high estimate of $1.98B for the next quarter, whereas the lowest estimate is $1.94B.
A total of 23 analysts have provided revenue estimates for ZBH’s current fiscal year. The highest revenue estimate was $7.8B, while the lowest revenue estimate was $7.66B, resulting in an average revenue estimate of $7.76B. In the same quarter a year ago, actual revenue was $7.39B, up 4.90% from the average estimate. Based on 23 analysts’ estimates, the company’s revenue will be $8.12B in the next fiscal year. The high estimate is $8.29B and the low estimate is $7.96B. The average revenue growth estimate for next year is up 4.70% from the average revenue estimate for this year.
